{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:08:33Z","timestamp":1790114913199,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jpba.2026.117682","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:37:01Z","timestamp":1785220621000},"page":"117682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identification of related substances in baloxavir marboxil using 2D-LC-Q-TOF\/MS"],"prefix":"10.1016","volume":"281","author":[{"given":"Zhi-tong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-rong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-juan","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7349-0121","authenticated-orcid":false,"given":"Xue-ling","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imene","family":"Adouani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3057-4705","authenticated-orcid":false,"given":"Tai-jun","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-cheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117682_bib1","first-page":"45","article-title":"Efficacy and safety analysis of baloxavir marboxil in the treatment of influenza","volume":"26","author":"Lin","year":"2024","journal-title":"Chin. J. Mod. Med."},{"key":"10.1016\/j.jpba.2026.117682_bib2","doi-asserted-by":"crossref","DOI":"10.1098\/rsos.241634","article-title":"Ultrasensitive turn-off fluorescent sensor for estimation of the new influenza antiviral prodrug baloxavir marboxil in its pharmaceutical formulation","volume":"12","author":"Gouda","year":"2025","journal-title":"R. Soc. Open. Sci."},{"key":"10.1016\/j.jpba.2026.117682_bib3","first-page":"641","article-title":"Clinical research progress on baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, for influenza treatment","volume":"41","author":"Huang","year":"2022","journal-title":"Chin. J. New. Drugs Clin. Rem."},{"key":"10.1016\/j.jpba.2026.117682_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jpba.2026.117682_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.resinv.2020.06.003","article-title":"Clinical application of baloxavir marboxil in the treatment of influenza","volume":"58","author":"Kuo","year":"2020","journal-title":"Respir. Investig."},{"key":"10.1016\/j.jpba.2026.117682_bib6","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/03007995.2021.1914942","article-title":"Cost-effectiveness of baloxavir marboxil compared with laninamivir for the treatment of influenza in patients at high risk for complications in Japan","volume":"37","author":"Dronova","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jpba.2026.117682_bib7","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/jac\/dkaa252","article-title":"Clinical outcomes of baloxavir versus oseltamivir in patients hospitalized with influenza A","volume":"75","author":"Shah","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2026.117682_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10337-017-3393-0","article-title":"Review on Implementation of Multivariate Approach for Forced Degradation Study and Impurity Profiling with Regulatory Considerations","volume":"81","author":"Patel","year":"2018","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2026.117682_bib9","first-page":"177","article-title":"Application of Forced Degradation Testing in Drug Development","volume":"37","author":"Ma","year":"2020","journal-title":"Chin. J. Mod. Appl. Pharm."},{"key":"10.1016\/j.jpba.2026.117682_bib10","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/jssc.201400266","article-title":"Determination of impurities and counterions of pharmaceuticals by capillary electromigration methods","volume":"37","author":"\u0160t\u011bp\u00e1nov\u00e1","year":"2014","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2026.117682_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jpba.2013.07.013","article-title":"Forced degradation and impurity profiling: recent trends in analytical perspectives","volume":"86","author":"Jain","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117682_bib12","article-title":"Ecofriendly stability-indicating UHPLC-PDA method for determination of the new influenza antiviral prodrug Baloxavir Marboxil; application to degradation kinetic studies and structure elucidation of the major degradation products using LC-MS","volume":"33","author":"Gouda","year":"2023","journal-title":"Sustain. Chem. Pharm."},{"key":"10.1016\/j.jpba.2026.117682_bib13","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1002\/jssc.202200020","article-title":"Kinetic degradation study for the first licensed anti-influenza polymerase inhibitor, baloxavir marboxil, using high-performance liquid chromatography-mass spectrometry","volume":"45","author":"Hafez","year":"2022","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2026.117682_bib14","first-page":"1128","article-title":"Advances in online two-dimensional liquid chromatography for natural product screening","volume":"58","author":"Lu","year":"2023","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2026.117682_bib15","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1080\/10408398.2021.1993128","article-title":"LC-Q-TOF-MS\/MS detection of food flavonoids: principle, methodology, and applications","volume":"63","author":"Yang","year":"2023","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.jpba.2026.117682_bib16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s44371-025-00329-2","article-title":"Comprehensive review on impurity profiling, control strategies and analytical methods of Baloxavir Marboxil and Baloxavir acid","volume":"2","author":"Lakka","year":"2025","journal-title":"Discov. Chem."},{"key":"10.1016\/j.jpba.2026.117682_bib17","unstructured":"International Council for Harmonisation, Q1A (R2) Stability Testing of New Drug Substances and Products, Geneva, 2003."},{"key":"10.1016\/j.jpba.2026.117682_bib18","unstructured":"International Council for Harmonisation, Q1B Stability Testing: Photostability Testing of New Drug Substances and Products, Geneva, 1996."},{"key":"10.1016\/j.jpba.2026.117682_bib19","article-title":"Stability-indicating method development and validation for quantitative estimation of assay and organic impurities of antiviral drug baloxavir marboxil in drug substance and pharmaceutical dosage form using HPLC and LC\u2013MS methods","volume":"37","author":"Nagulancha","year":"2023","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2026.117682_bib20","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1021\/acs.oprd.3c00502","article-title":"Practical Manufacturing Process for Baloxavir Marboxil: Efficient Route to a Tricyclic Triazinanone Scaffold","volume":"28","author":"Fukui","year":"2024","journal-title":"Org. Process. Res. Dev."},{"key":"10.1016\/j.jpba.2026.117682_bib21","unstructured":"National Medical Products Administration, Originator\u2019s Quality Standard for Baloxavir Marboxil Tablets, Standard No. JX20210043, China, 2021."},{"key":"10.1016\/j.jpba.2026.117682_bib22","unstructured":"International Council for Harmonisation, Q2 (R2): Validation of Analytical Procedures, Geneva, Switzerland, 2023."},{"key":"10.1016\/j.jpba.2026.117682_bib23","first-page":"64","article-title":"Catalytic asymmetric oxidation of sulfides to sulfoxides using (R)-6,6\u2019-Diphenyl-BINOL as a","volume":"131","author":"Choudary","year":"2019","journal-title":"chiral Ligand J. Chem. Sci."},{"key":"10.1016\/j.jpba.2026.117682_bib24","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1007\/s00216-019-01813-2","article-title":"Investigation of factors influencing the separation of diastereomers of phosphorothioated oligonucleotides","volume":"411","author":"Enmark","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2026.117682_bib25","unstructured":"International Council for Harmonisation, M7(R2): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk, Geneva, Switzerland, 2023."},{"key":"10.1016\/j.jpba.2026.117682_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2026.117554","article-title":"Comprehensive impurity profiling and stability assessment of indacaterol maleate integrating LC\u2013MS and in silico genotoxicity","volume":"278","author":"Ayd\u0131n","year":"2026","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117682_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2026.117495","article-title":"Strategic characterization of active pharmaceutical ingredients co-eluting impurities: Identification, enrichment and structural elucidation of an oxidized impurity from mobocertinib drug substance","volume":"277","author":"Dai","year":"2026","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117682_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.116926","article-title":"Impurity profiling and stability analysis of enzalutamide: Identification, genotoxicity assessment, and development of UHPLC methods for critical impurities","volume":"263","author":"Oktar Uzun","year":"2025","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852600350X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852600350X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:44:34Z","timestamp":1790113474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170852600350X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":28,"alternative-id":["S073170852600350X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117682","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of related substances in baloxavir marboxil using 2D-LC-Q-TOF\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117682"}}